Thin Gingival BiotypeNCT07317856
Efficacy of Microneedling With Hyaluronic Acid Injection for Gingival Augmentation in Thin Gingival Phenotype
A study testing Microneedling (MN) and Microneedling + Injectable Hyaluronic Acid (MN + HA) in people with Thin Gingival Biotype, run by University of Baghdad at 1 site in Iraq.
Trial summary
This randomized controlled trial adheres to the Consolidated Standards of Reporting Trials (CONSORT) 2010 guidelines and the Declaration of Helsinki ethical principles for medical research. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Thin Gingival Biotype
- What is being tested?
- Microneedling (MN) and Microneedling + Injectable Hyaluronic Acid (MN + HA)
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteIraq
- Study dates
- Jan 2026to Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged ≥18 years from both sexes
- Systemically healthy individuals with no history of chronic systemic diseases.
- Participants with positive periodontal probe transparency in anterior teeth.
- Adequate oral hygiene (full-mouth plaque score ≤20%).
- Non-smokers or former smokers who quit ≥12 months prior to enrollment.
- Willingness to comply with study procedures, attend follow-up visits, and provide written informed consent.
Who cannot join
- Pregnancy or lactation.
- Use of medications affecting periodontal status or wound healing (e.g., systemic corticosteroids, bisphosphonates) within the past six months
- History of periodontal surgery or soft-tissue augmentation procedures at the target sites
- Active periodontal disease (probing depth >3 mm, clinical attachment loss >2 mm) or gingival inflammation (bleeding on probing ≥ 10%).
- Untreated carious lesions or periapical pathology in the study area.
- Systemic conditions that impair healing (e.g., uncontrolled diabetes mellitus, immunocompromised states).
Show all 9Show fewer
- Use of anti-inflammatory or anticoagulant medications within two weeks prior to treatment.
- Known allergy to hyaluronic acid or components of the microneedling device.
- Presence of heavy gingival pigmentation at the target sites.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Murtadha Mohammed Humadi Dentist, B.D.S contact
Iraq1 site
University of Baghdad
Baghdad, 10047
College of Dentistry, University of Baghdad, 0096414169394, master@codental.uobaghdad.edu.iq
About this study
Official title: Efficacy of Microneedling With Hyaluronic Acid Injection for Gingival Augmentation in Thin Gingival Phenotype: A Split- Mouth Randomized Clinical Trial
This randomized controlled trial adheres to the Consolidated Standards of Reporting Trials (CONSORT) 2010 guidelines and the Declaration of Helsinki ethical principles for medical research. The study complies with Good Clinical Practice (GCP) standards and will be prospectively registered with ClinicalTrials.gov to ensure transparency and accountability. A crossover design is implemented to ensure all participants receive both treatment modalities-microneedling (MN) alone and microneedling combined with injectable hyaluronic acid (MN + HA)-following an appropriate washout period, promoting equitable access while maintaining scientific rigor through within-subject comparisons.
Baseline Preparation
Read more
All enrolled participants receive comprehensive periodontal therapy at baseline, including supragingival and subgingival scaling using ultrasonic instrumentation combined with hand instruments. Standardized oral hygiene protocols are established with identical oral care products provided to each subject, including a soft-bristled toothbrush and interdental cleaning aids. All participants receive instruction in proper brushing technique with emphasis on twice-daily maintenance to ensure consistent plaque control throughout the trial.
Microneedling Intervention
The MN intervention comprises three sessions spaced seven days apart. Following baseline clinical assessment (plaque index, bleeding on probing, probing depth, clinical attachment level, keratinized tissue width, and gingival thickness) with standardized photographs, topical anesthesia is applied for one minute followed by infiltration anesthesia with 2% lidocaine with 1:100,000 epinephrine. The Dr. Pen Ultima A6 with a 24-pin cartridge is vertically inserted through keratinized gingiva until bone contact is achieved, treating from the mesial central incisor to the distal canine. Treatment ends when uniform pin-point bleeding is achieved. Post-procedure care includes gentle saline rinse, avoidance of brushing for 24 hours, twice-daily 0.12% chlorhexidine mouthwash for seven days, and avoidance of NSAIDs. Clinical reassessment occurs at 3 and 6 months.
Microneedling Plus Hyaluronic Acid Intervention
Following identical baseline assessment, anesthesia, and microneedling as the MN group, cross-linked hyaluronic acid (16-20 mg/mL, 200-400 µm particle size) is injected using 30-gauge needles (8 mm) with 1 mL insulin syringes. Two anatomical sites per area receive injections: 3 mm apical to the free gingival margin and apical to the mucogingival junction. The needle is inserted at 45 degrees, advanced 2-3 mm until blanching occurs, with a total volume of 0.04 mL per site (0.02 mL per point) at a rate not exceeding 0.01 mL per 10 seconds. Post-injection circular massage for 2-3 minutes ensures uniform distribution. Three sessions are performed seven days apart with identical post-procedure care and follow-up assessments at 3 and 6 months.
Outcome Measures
The primary outcome is the change in gingival thickness (millimeters) at treated sites from baseline to 6 months post-intervention, measured using transgingival probing. Secondary outcomes include changes in keratinized gingiva width, periodontal parameters (Plaque Index, Bleeding on Probing, Probing Pocket Depth, and Clinical Attachment Level), and patient-reported outcomes for pain, swelling, discomfort, and bleeding measured using visual analog scales at 2, 24, and 48 hours post-intervention. This comprehensive protocol ensures robust evaluation of both objective tissue augmentation and subjective patient experiences across both treatment modalities.
- Conditions
- Thin Gingival Biotype
- Being tested
- Microneedling (MN), Microneedling + Injectable Hyaluronic Acid (MN + HA)
- Keywords
- Hyaluronic acid, microneedling, soft tissue regeneration, soft tissue augmentation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Microneedling (MN)Procedure or surgery
A derma pen (Dr. Pen Ultima A6) with 24-pin cartridge will be used for microneedling. The device will be vertically inserted through the keratinized gingiva at each treatment site until contact with the underlying hard tissue (bone) is reached. Treatment will extend from the mesial line angle of the central incisor to the distal line angle of the canine. The treatment endpoint is identified as uniform pin-point bleeding, which is easily controlled with gentle pressure. The microneedling procedure will be repeated for three sessions, with each session spaced 7 days apart. This protocol ensures consistent intervention dosage and timing to optimize gingival augmentation outcomes while allowing adequate healing time between sessions.
Microneedling + Injectable Hyaluronic Acid (MN + HA)Combination product
A derma pen (Dr. Pen Ultima A6) with 24-pin cartridge will be used for microneedling. The device will be vertically inserted through the keratinized gingiva at each treatment site until contact with the underlying hard tissue (bone) is reached. Treatment will extend from the mesial line angle of the central incisor to the distal line angle of the canine.The hyaluronic acid injection protocol for gingival augmentation utilizes cross-linked hyaluronic acid at 16-20 mg/mL concentration with 200-400 μm particle size, delivered via sterile pre-filled syringes using 30-gauge microneedles (8mm) with 1mL insulin syringes marked at 0.02mL intervals. Following topical anesthetic application for 2-3 minutes, the injection technique targets two anatomical sites per treatment area: the first point located 3mm apical to the free gingival margin and the second point apical to the mucogingival junction. Post-injection gentle circular massage for 2-3 minutes ensures uniform distribution of the material
| Study group | Role | What they receive |
|---|---|---|
| Microneedling (MN) Group | Active comparator | Control group Receives: Procedure: Microneedling (MN) |
| Microneedling + Injectable Hyaluronic Acid (MN + HA) Group | Experimental | Test group Receives: Combination Product: Microneedling + Injectable Hyaluronic Acid (MN + HA) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in gingival thickness
The primary outcome measure is the change in gingival thickness (in millimeters) at treated sites from baseline to 6 months post-intervention, as determined by transgingival probing method.
Measured: 6 months
Secondary outcomes (6)
Change in width of keratinized gingiva
Measured: 6 months
Plaque Index (PI)
Measured: 6 months
Bleeding on probing (BOP)
Measured: 6 months
Clinical attachment level (CAL)
Measured: 6 months
Change in probing depth
Measured: 6 months
Patient-reported outcomes
Patient-reported outcomes assessed via visual analog scales for pain, swelling, discomfort and bleeding at 2 hours, 8 hours, 24 hours, and 48 hours following each intervention session.
Measured: 48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2026
- Study startJan 2026 (estimated)
- Primary completionSep 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thin Gingival BiotypeStudies of the same condition, open and under way.
- More trials run by University of BaghdadThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study will be a 6-month follow-up, split mouth, double blind, prospective randomized controlled Clinical trial
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Baghdad
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Murtadha Muhammed Humadi, University of Baghdad
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07317856
- Sponsor's protocol ID
- 1114
- Status last verified
- Dec 2025
- First submitted
- 19 Dec 2025
- Last updated
- 5 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Microneedling With Hyaluronic Acid Injection for Gingival Augmentation in Thin Gingival Phenotype: A Split- Mouth Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT07317856
- Acronym / sponsor ID
- 1114
- Conditions
- Thin Gingival Biotype
- Keywords
- Hyaluronic acid, microneedling, soft tissue regeneration, soft tissue augmentation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- University of BaghdadUniversity, hospital or other
- Study start
- Jan 2026 (estimated)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 5 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled trial adheres to the Consolidated Standards of Reporting Trials (CONSORT) 2010 guidelines and the Declaration of Helsinki ethical principles for medical research. The study complies with Good Clinical Practice (GCP) standards and will be prospectively registered with ClinicalTrials.gov to ensure transparency and accountability. A crossover design is implemented to ensure all participants receive both treatment modalities-microneedling (MN) alone and microneedling combined with injectable hyaluronic acid (MN + HA)-following an appropriate washout period, promoting equitable access while maintaining scientific rigor through within-subject comparisons.
Baseline Preparation
All enrolled participants receive comprehensive periodontal therapy at baseline, including supragingival and subgingival scaling using ultrasonic instrumentation combined with hand instruments. Standardized oral hygiene protocols are established with identical oral care products provided to each subject, including a soft-bristled toothbrush and interdental cleaning aids. All participants receive instruction in proper brushing technique with emphasis on twice-daily maintenance to ensure consistent plaque control throughout the trial.
Microneedling Intervention
The MN intervention comprises three sessions spaced seven days apart. Following baseline clinical assessment (plaque index, bleeding on probing, probing depth, clinical attachment level, keratinized tissue width, and gingival thickness) with standardized photographs, topical anesthesia is applied for one minute followed by infiltration anesthesia with 2% lidocaine with 1:100,000 epinephrine. The Dr. Pen Ultima A6 with a 24-pin cartridge is vertically inserted through keratinized gingiva until bone contact is achieved, treating from the mesial central incisor to the distal canine. Treatment ends when uniform pin-point bleeding is achieved. Post-procedure care includes gentle saline rinse, avoidance of brushing for 24 hours, twice-daily 0.12% chlorhexidine mouthwash for seven days, and avoidance of NSAIDs. Clinical reassessment occurs at 3 and 6 months.
Microneedling Plus Hyaluronic Acid Intervention
Following identical baseline assessment, anesthesia, and microneedling as the MN group, cross-linked hyaluronic acid (16-20 mg/mL, 200-400 µm particle size) is injected using 30-gauge needles (8 mm) with 1 mL insulin syringes. Two anatomical sites per area receive injections: 3 mm apical to the free gingival margin and apical to the mucogingival junction. The needle is inserted at 45 degrees, advanced 2-3 mm until blanching occurs, with a total volume of 0.04 mL per site (0.02 mL per point) at a rate not exceeding 0.01 mL per 10 seconds. Post-injection circular massage for 2-3 minutes ensures uniform distribution. Three sessions are performed seven days apart with identical post-procedure care and follow-up assessments at 3 and 6 months.
Outcome Measures
The primary outcome is the change in gingival thickness (millimeters) at treated sites from baseline to 6 months post-intervention, measured using transgingival probing. Secondary outcomes include changes in keratinized gingiva width, periodontal parameters (Plaque Index, Bleeding on Probing, Probing Pocket Depth, and Clinical Attachment Level), and patient-reported outcomes for pain, swelling, discomfort, and bleeding measured using visual analog scales at 2, 24, and 48 hours post-intervention. This comprehensive protocol ensures robust evaluation of both objective tissue augmentation and subjective patient experiences across both treatment modalities.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- The study will be a 6-month follow-up, split mouth, double blind, prospective randomized controlled Clinical trial
| Arm | Type | Receives |
|---|---|---|
| Microneedling (MN) Group | Active comparator | Procedure: Microneedling (MN)Control group |
| Microneedling + Injectable Hyaluronic Acid (MN + HA) Group | Experimental | Combination Product: Microneedling + Injectable Hyaluronic Acid (MN + HA)Test group |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adults aged ≥18 years from both sexes
- Systemically healthy individuals with no history of chronic systemic diseases.
- Participants with positive periodontal probe transparency in anterior teeth.
- Adequate oral hygiene (full-mouth plaque score ≤20%).
- Non-smokers or former smokers who quit ≥12 months prior to enrollment.
Key exclusion criteria (9 listed)
- Pregnancy or lactation.
- Use of medications affecting periodontal status or wound healing (e.g., systemic corticosteroids, bisphosphonates) within the past six months
- History of periodontal surgery or soft-tissue augmentation procedures at the target sites
- Active periodontal disease (probing depth >3 mm, clinical attachment loss >2 mm) or gingival inflammation (bleeding on probing ≥ 10%).
- Untreated carious lesions or periapical pathology in the study area.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Microneedling (MN)A derma pen (Dr. Pen Ultima A6) with 24-pin cartridge will be used for microneedling. The device will be vertically inserted through the keratinized gingiva at each treatment site until contact with the underlying hard tissue (bone) is reached. Treatment will extend from the mesial line angle of the central incisor to the distal line angle of the canine. The treatment endpoint is identified as uniform pin-point bleeding, which is easily controlled with gentle pressure. The microneedling procedure will be repeated for three sessions, with each session spaced 7 days apart. This protocol ensures consistent intervention dosage and timing to optimize gingival augmentation outcomes while allowing adequate healing time between sessions. | Procedure or surgery | Microneedling (MN) Group |
| Microneedling + Injectable Hyaluronic Acid (MN + HA)A derma pen (Dr. Pen Ultima A6) with 24-pin cartridge will be used for microneedling. The device will be vertically inserted through the keratinized gingiva at each treatment site until contact with the underlying hard tissue (bone) is reached. Treatment will extend from the mesial line angle of the central incisor to the distal line angle of the canine.The hyaluronic acid injection protocol for gingival augmentation utilizes cross-linked hyaluronic acid at 16-20 mg/mL concentration with 200-400 μm particle size, delivered via sterile pre-filled syringes using 30-gauge microneedles (8mm) with 1mL insulin syringes marked at 0.02mL intervals. Following topical anesthetic application for 2-3 minutes, the injection technique targets two anatomical sites per treatment area: the first point located 3mm apical to the free gingival margin and the second point apical to the mucogingival junction. Post-injection gentle circular massage for 2-3 minutes ensures uniform distribution of the material | Combination product | Microneedling + Injectable Hyaluronic Acid (MN + HA) Group |
Primary outcome
Change in gingival thickness
Time frame: 6 months
The primary outcome measure is the change in gingival thickness (in millimeters) at treated sites from baseline to 6 months post-intervention, as determined by transgingival probing method.
6 secondary outcomes
Change in width of keratinized gingiva
Time frame: 6 months
Plaque Index (PI)
Time frame: 6 months
Bleeding on probing (BOP)
Time frame: 6 months
Clinical attachment level (CAL)
Time frame: 6 months
Change in probing depth
Time frame: 6 months
Patient-reported outcomes
Time frame: 48 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Thin Gingival Biotype
Active, not recruiting
i-PRF for Gingival Phenotype Modification
Thin Gingival Biotype
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Murtadha Mohammed Humadi Dentist, B.D.S contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Microneedling (MN) and Microneedling + Injectable Hyaluronic Acid (MN + HA) in people with Thin Gingival Biotype, run by University of Baghdad at 1 site in Iraq.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iraq. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Murtadha Mohammed Humadi Dentist, B.D.S (009647731843878, Mortada.naima2405@codental.uobaghdad.edu.iq), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in gingival thickness (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2026.